Atabak Mokari. - 01 Sep 2022 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Chief Financial Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari.
Issuer symbol
CORT
Transactions as of
01 Sep 2022
Net transactions value
+$20,602
Form type
4
Filing time
06 Sep 2022, 20:50:14 UTC
Previous filing
15 Feb 2023
Next filing
03 Mar 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Award $20,602 +793 $25.98 793 01 Sep 2022 Direct F1, F2
transaction CORT Common Stock Award $0 +793 +100% $0.000000 1,586 01 Sep 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2012 Incentive Award Plan on September 1, 2022.
F2 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements under the Purchase Plan.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.